Results 121 to 130 of about 22,402 (163)

Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. [PDF]

PLoS One
Li H, Pemov A, Allaway R, Muir DF, Chang LJ, Banerjee J, Scott AJ, Nagy JMW, Liu J, Carrió M, Mazuelas H, Yachnis A, Lee SY, Zhang X, Lyu Y, Stewart DR, Hirbe A, Blakeley JO, Serra E, Wallis D, Wallace MR.   +20 more
europepmc   +1 more source

Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. [PDF]

Cancer Res, 2012
See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO.   +4 more
europepmc   +1 more source

Comparative oncogenomics implicates the neurofibromin 1 gene (NF1) as a breast cancer driver. [PDF]

Genetics, 2012
Wallace MD, Pfefferle AD, Shen L, McNairn AJ, Cerami EG, Fallon BL, Rinaldi VD, Southard TL, Perou CM, Schimenti JC.   +9 more
europepmc   +1 more source

Neurovascular Issues in Neurofibromatosis Type I: Focus on Intracranial Stenosis. [PDF]

Life (Basel)
Zedde M, Pascarella R.
europepmc   +1 more source

Ataluren-Induced Functional Restoration of Neurofibromin in Fibroblasts From Neurofibromatosis Type 1 Patients With Nonsense Mutations. [PDF]

MedComm (2020)
Kim S, Do H, Heo SH, Kang M, Hwang S, Kim D, Chang MH, Kim K, Lee BH.   +8 more
europepmc   +1 more source

TEAD inhibitors synergize with MEK, SHP2 and mTOR inhibitors in NF1 and NF2 cell lines. [PDF]

MicroPubl Biol
Yang Y, Gurunathan S, Schechter S, Field J.   +3 more
europepmc   +1 more source

Ganglioneuroblastoma associated with neurofibromatosis type 1: a case report with a systematic review. [PDF]

Front Oncol
Zhang Q, Su S, Geng G, Bai Y, Hu W, Zhang W, Zhang H, Wang G.   +7 more
europepmc   +1 more source

Case Report: Clinical case of a giant plexiform neurofibroma of the liver in a patient with deletion of exon 1 of the NF1 gene. [PDF]

Front Oncol
Idrissova Z, Orazgaliyeva M, Kovaleva K, Seilkhanova Z, Rakhimbekova F, Zhaksybek M, Myrzamuratova D.   +6 more
europepmc   +1 more source

Neurofibromatosis Type 1: Genetic Mechanisms and Advances in Therapeutic Innovation. [PDF]

Cancers (Basel)
Lu Y, Xu M, Chen X, Xu H, Sun N, Weisgerber KE, Bai RY.   +6 more
europepmc   +1 more source